Helen Pettinati, Ph.D., Director of the Addiction Treatment Research and Medication Development Division, Center for the Studies of Addiction, was recently honored by the Butler Center for Research at Hazelden with the Dan Anderson Research Award, for her randomized clinical trial examining the effects treating alcohol dependence and depression concurrently. The award is for a single published article by a researcher who has advanced the scientific knowledge of addiction treatment and recovery.
Pettinati earned the award for her study, "A Double-Blind, Placebo-Controlled Trial Combining Sertraline and Naltrexone for Treating Co-Occurring Depression and Alcohol Dependence," published in the June 2010 issue of the American Journal of Psychiatry. The study focused on 170 individuals attending outpatient treatment for alcohol dependence, all of whom had a co-occurring depressive disorder. All participants received weekly cognitive behavioral therapy sessions and were randomly assigned to one of four treatment groups: a combined sertraline and naltrexone group, a naltrexone-only group, a sertraline-only group, and a placebo control group. Participants taking both medications were compared to the other three groups on a number of treatment outcomes, including total abstinence, time to relapse, and presence of depression symptoms.
“The co-occurrence of depression and alcohol dependence is highly prevalent and difficult to treat successfully,” said Pettinati. "The present findings suggest that patients with both disorders would benefit from combination treatment with an antidepressant and anti-craving medication for alcohol dependence.” Dr. Charles O'Brien nominated Dr. Pettinati for the award, stating her work "can be expected to have a major impact on the treatment of alcoholic patients [with] depression.”
The full press release from Hazelden is available here: http://www.hazelden.org/web/public/pr101208.page.
Penn Medicine is one of the world's leading academic medical centers, dedicated to the related missions of medical education, biomedical research, and excellence in patient care. Penn Medicine consists of the Raymond and Ruth Perelman School of Medicine at the University of Pennsylvania (founded in 1765 as the nation's first medical school) and the University of Pennsylvania Health System, which together form a $4.3 billion enterprise.
The Perelman School of Medicine has been ranked among the top five medical schools in the United States for the past 17 years, according to U.S. News & World Report's survey of research-oriented medical schools. The School is consistently among the nation's top recipients of funding from the National Institutes of Health, with $392 million awarded in the 2013 fiscal year.
The University of Pennsylvania Health System's patient care facilities include: The Hospital of the University of Pennsylvania -- recognized as one of the nation's top "Honor Roll" hospitals by U.S. News & World Report; Penn Presbyterian Medical Center; Chester County Hospital; Penn Wissahickon Hospice; and Pennsylvania Hospital -- the nation's first hospital, founded in 1751. Additional affiliated inpatient care facilities and services throughout the Philadelphia region include Chestnut Hill Hospital and Good Shepherd Penn Partners, a partnership between Good Shepherd Rehabilitation Network and Penn Medicine.
Penn Medicine is committed to improving lives and health through a variety of community-based programs and activities. In fiscal year 2013, Penn Medicine provided $814 million to benefit our community.